PNOC019/NICHE-HGG
A Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Combination Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Glioma (HGG)
Brain and other Central Nervous System (CNS) Tumours
PNOC019 is a clinical trial for children and young adults who have progressive or recurring high-grade gliomas (HGG). HGGs are fast growing, aggressive brain cancers and if they recur after initial treatment, there are no effective treatment options. Immunotherapy has been shown to be a promising treatment for a number of other aggressive cancers.
This study will examine the effectiveness of an immunotherapy agent, nivolumab, given to children and young adults with HGG before and after surgery. The drug acts as an immune checkpoint inhibitor to block a protein that stops the immune system from working properly. Immunotherapy with nivolumab in children and young adults with HGG may help the body’s immune system attack cancer, and may interfere with the ability of tumor cells to grow and spread.
PNOC019 will measure the changes in tumours and compare the results to archived non-treated samples. The study will also evaluate the safety and tolerability of nivolumab, and determine how many participants remain free of tumour growth.
Disease stage: Recurrent or Progressive High-Grade Glioma (HGG)
Patient age range: 6 months to 25 years of age
Trial sponsors:
- National: ANZCHOG
- International: Pediatric Neuro-Oncology Consortium
